Xu‐Chao Zhang

Potential Predictive Value of <i>TP53</i> and <i>KRAS</i> Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma

Zhong‐Yi Dong, Wen‐Zhao Zhong, Xu‐Chao Zhang et al. · Clinical Cancer Research · 2016 · 992 citations

Medicine, Immunology, Oncology +17

Genome-wide association analysis identifies new lung cancer susceptibility loci in never-smoking women in Asia

Qing Lan, Chao A. Hsiung, Keitaro Matsuo et al. · Nature Genetics · 2012 · 354 citations · Full text

Life Sciences, Genetics, Molecular Genetics +13

Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression

Xu‐Chao Zhang, Shirley Zhang, Xue‐Ning Yang et al. · Molecular Cancer · 2010 · 298 citations · Full text

Medicine, Oncology, Pathology +17

Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 <i>EGFR</i>-Mutant Non–Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study

Wen‐Zhao Zhong, Ke‐Neng Chen, Chun Chen et al. · Journal of Clinical Oncology · 2019 · 267 citations

Medicine, Oncology, Pharmacology +15

Relative Abundance of <i>EGFR</i> Mutations Predicts Benefit From Gefitinib Treatment for Advanced Non–Small-Cell Lung Cancer

Qing Zhou, Xu‐Chao Zhang, Zhihong Chen et al. · Journal of Clinical Oncology · 2011 · 247 citations

Medicine, Oncology, Pharmacology +17